Centrexion Therapeutics to Present CNTX-4975 Clinical Data at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting

BOSTON, Mass., March 1, 2018 – Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced it will present Phase 2b data of CNTX-4975 for the treatment of moderate to severe osteoarthritis knee pain at 4:00 p.m. CST on Tuesday, March 6 at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting taking place from March 6-10, 2018 at the Ernest N. Morial Convention Center in New Orleans, LA.

This entry was posted in Recent Development News: Q1 - 2018, Recent Developments. Bookmark the permalink.
Read Full Article »